Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

TSX:OPS - Post Discussion

Opsens Inc > Look at the chart...
View:
Post by Qccity1 on Dec 02, 2022 1:46pm

Look at the chart...

In Feb 2021, Opsens has announced a bought deal offering at a price of 1.80$ per common share. The stock was at 1.97$ at the time. Take at the look at the stock chart after this deal...
Comment by prophetoffactz on Dec 02, 2022 2:25pm
Today's sell-off was a gift. The NASDAQ Biotech ETF is now up marginaly over the last 3 months. OPS is down about 34%.
Comment by tannin on Dec 05, 2022 3:58am
Your right prophetoffactz, current ops price a gift........glta
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities